UY28391A1 - Metodos y composiciones para tratar artritis reumatoide - Google Patents

Metodos y composiciones para tratar artritis reumatoide

Info

Publication number
UY28391A1
UY28391A1 UY28391A UY28391A UY28391A1 UY 28391 A1 UY28391 A1 UY 28391A1 UY 28391 A UY28391 A UY 28391A UY 28391 A UY28391 A UY 28391A UY 28391 A1 UY28391 A1 UY 28391A1
Authority
UY
Uruguay
Prior art keywords
methods
compositions
integrin
alpha
treat
Prior art date
Application number
UY28391A
Other languages
English (en)
Inventor
Messersmith Elizabeth
Freedman Stephen B Konradi
Andrei W Konradi
Lieberburg Ivan
Michael A Pleiss
Shopp George
Theodore A Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33551975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28391(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of UY28391A1 publication Critical patent/UY28391A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La solicitud se refiere a métodos y composiciones para tratar la artritis reumatoide administrando una terapia combinada que comprende metotrexato y un anticuerpo de la integrina alfa-4 o u fragmento con propiedades de fijación de antígeno inmunológicamente activo en cantidades terapéuticamente afectivas. La solicitud también se refiere a métodos y composiciones para tratar la artritis reumnatoide administrando al mamífero una terapia combinada que comprende metotrexato y un antagonista de la integrina alfa-4 de molécula pequena que inhibe la interacción de la integrina alfa-4 (integrina a4) con la VCAM-1.La invneicón también se refiere a métodos para preparar los compuesots y a métodos para utilizar los compuestos y composiciones.
UY28391A 2003-06-25 2004-06-25 Metodos y composiciones para tratar artritis reumatoide UY28391A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48221103P 2003-06-25 2003-06-25

Publications (1)

Publication Number Publication Date
UY28391A1 true UY28391A1 (es) 2004-12-31

Family

ID=33551975

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28391A UY28391A1 (es) 2003-06-25 2004-06-25 Metodos y composiciones para tratar artritis reumatoide

Country Status (12)

Country Link
US (2) US20050074451A1 (es)
EP (2) EP1635822A4 (es)
JP (2) JP2007524626A (es)
AR (1) AR044927A1 (es)
AU (2) AU2004251754A1 (es)
CA (2) CA2529873A1 (es)
CL (1) CL2004001621A1 (es)
NZ (1) NZ544367A (es)
PE (1) PE20050232A1 (es)
TW (1) TW200509930A (es)
UY (1) UY28391A1 (es)
WO (2) WO2005000246A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005070921A1 (en) * 2004-01-23 2005-08-04 Elan Pharmaceuticals, Inc. Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
CA2559408C (en) 2004-03-15 2014-05-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
WO2005111020A2 (en) * 2004-04-30 2005-11-24 Elan Pharmaceuticals, Inc. Pyrimidine hydantoin analogues which inhibit leukocyte adhesion mediated by vla-4
CA2573245C (en) * 2004-07-08 2013-10-01 Elan Pharmaceuticals, Inc. Multivalent vla-4 antagonists comprising polymer moieties
EP1817025A2 (en) 2004-11-23 2007-08-15 PTC Therapeutics, Inc. Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
DE602005008639D1 (de) 2004-12-02 2008-09-11 Can Fite Biopharma Ltd Behandlung von entzündungen
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
EP1881982B1 (en) 2005-05-20 2013-11-20 Elan Pharmaceuticals Inc. Imidazolone phenylalanine derivatives as vla-4 antagonists
MX2008000291A (es) 2005-07-08 2008-04-04 Elan Pharm Inc Preparacion de conjugados polimericos de compuestos de aditivos terapeuticos, agricolas y alimentarios.
NZ567270A (en) * 2005-09-29 2011-06-30 Elan Pharm Inc Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
JP5081976B2 (ja) * 2007-10-22 2012-11-28 ベクトン・ディキンソン・アンド・カンパニー オルガノポリシロキサンを含む懸濁液においてタンパク質の凝集を評価するための方法
JP2011528321A (ja) * 2008-06-21 2011-11-17 ケンバー，エルエルシー ニュートリゲノミクス方法および組成
PL2442651T3 (pl) * 2009-06-19 2015-12-31 Teva Pharma Leczenie stwardnienia rozsianego za pomocą lakwinimodu
US8598203B2 (en) * 2009-07-30 2013-12-03 Teva Pharmaceutical Industries, Ltd. Treatment of Crohn's disease with laquinimod
EP2467372B1 (en) 2009-08-10 2016-05-18 Teva Pharmaceutical Industries Ltd. Treatment of bdnf-related disorders using laquinimod
US20110217295A1 (en) * 2010-03-03 2011-09-08 Asi Haviv Treatment of lupus arthritis using laquinimod
PE20181523A1 (es) * 2010-03-03 2018-09-24 Teva Pharma Tratamiento de lupus nefritis usando laquinimod
CN105796556A (zh) * 2010-03-03 2016-07-27 泰华制药工业有限公司 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
PT3170508T (pt) 2010-06-04 2020-01-16 Wyeth Llc Formulações de vacinas
BR112014008731A2 (pt) 2011-10-12 2017-04-25 Teva Pharma tratamento de esclerose múltipla com combinação de laquinimode e fingolimode
MX2014009373A (es) 2012-02-03 2014-08-27 Teva Pharma Uso de laquinimod para tratar pacientes con enfermedad de crohn que fallaron en la terapia de anti-tnfa de primera linea.
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113720A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
JP2015508752A (ja) 2012-02-03 2015-03-23 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AU2014324426A1 (en) 2013-09-30 2016-04-21 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
EP3015069A1 (en) 2014-10-30 2016-05-04 Universitätsklinikum Jena Apparatus for suspended ultrasonography and corresponding method
WO2016145258A1 (en) 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
DK3412660T3 (da) 2016-02-05 2020-11-30 Ea Pharma Co Ltd Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
US10914720B2 (en) 2016-02-10 2021-02-09 Becton Dickinson France Method to evaluate the stability of a protein-based formulation
WO2018085552A1 (en) * 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
WO2019172213A1 (ja) * 2018-03-05 2019-09-12 国立大学法人横浜国立大学 ナノ微粒子、及びナノ微粒子の製造方法、並びに抗腫瘍剤
US11479617B2 (en) 2018-08-27 2022-10-25 Carnegie Mellon University Chelator-functionalized glycosaminoglycans
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
EP3873900A1 (en) 2018-10-30 2021-09-08 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
AU2020329207B2 (en) 2019-08-14 2024-02-29 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1080503A (en) * 1965-07-02 1967-08-23 Smith & Nephew Substituted acetic acids and a process for their preparation
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc Heterocyclic amides as cell adhesion inhibitors
ZA986827B (en) * 1997-07-31 2000-05-02 Athena Neurosciences Inc Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4.
AR016133A1 (es) * 1997-07-31 2001-06-20 Wyeth Corp Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
BR9811594A (pt) * 1997-07-31 2000-09-05 Elan Pharm Inc Compostos de dipeptìdeo sulfonilados que inibem adesão de leucócito mediada por vla-4
US6489300B1 (en) * 1997-07-31 2002-12-03 Eugene D. Thorsett Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4
US20020198172A1 (en) * 1997-12-01 2002-12-26 Sandage Bobby W. Method of treating motor neuron diseases and demyelinating diseases with citicoline
WO2000043369A1 (en) * 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
EP1144388B1 (en) * 1999-01-22 2010-01-13 Elan Pharmaceuticals, Inc. Acyl derivatives which treat vla-4 related disorders
WO2001056994A1 (en) * 2000-02-04 2001-08-09 Biogen, Inc. Integrin antagonists
PE20020384A1 (es) * 2000-07-21 2002-05-28 Schering Corp PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
ATE512163T1 (de) * 2002-02-25 2011-06-15 Elan Pharm Inc Verabreichung von mitteln zur behandlung von entzündungen
TW200307671A (en) * 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) * 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

Also Published As

Publication number Publication date
AU2004251754A1 (en) 2005-01-06
EP1635871A4 (en) 2007-07-18
AU2004251754A2 (en) 2005-01-06
US20050074451A1 (en) 2005-04-07
JP2007524626A (ja) 2007-08-30
NZ544367A (en) 2009-12-24
WO2005000244A3 (en) 2005-09-29
TW200509930A (en) 2005-03-16
AR044927A1 (es) 2005-10-12
CA2528723A1 (en) 2005-01-06
AU2004251750A1 (en) 2005-01-06
WO2005000244A2 (en) 2005-01-06
JP2007526230A (ja) 2007-09-13
US7605166B2 (en) 2009-10-20
AU2004251750A2 (en) 2005-01-06
EP1635822A4 (en) 2009-06-24
EP1635871A2 (en) 2006-03-22
CL2004001621A1 (es) 2005-03-28
CA2529873A1 (en) 2005-01-06
PE20050232A1 (es) 2005-04-01
EP1635822A2 (en) 2006-03-22
WO2005000246A2 (en) 2005-01-06
US20050065192A1 (en) 2005-03-24
WO2005000246A3 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
UY28391A1 (es) Metodos y composiciones para tratar artritis reumatoide
CL2010000788A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo que se une a integrina alfa-v-beta-6; composicion farmaceutica que lo comprende; uso para tratar o prevenir fibrosis, psoriasis, cancer, daño agudo de pulmon y sindrome de alpont; uso para detectar integrina alfa-v-beta-6 (div. sol. no. 513-03).
ECSP12006607A (es) Anticuerpos antagonistas anti-cd40 monoclonales y métodos para su uso
AR066916A1 (es) Anticuerpos conra c3b y metodos para la prevenc ion y el tratamiento de trastornos asociados con el complemento. composicion farmaceutica.
BR112014008764A2 (pt) composições para o tratamento de artrite reumatóide e métodos de seu uso
CL2008003788A1 (es) Composicion farmaceutico que comprende a) el anticuerpo b-ly1 humanizado (anti-cd20/antigeno de referenciacion restringida del linfocito b humano/bp35, de tipo ii), b) opcionalmente de 0,001% al 1%p/v de por lo menos un surfactante, y c) de 1 a 100 mm de un tampon; uso para tratar enfermedades relacionadas con cd20.
CY1118098T1 (el) Fc riib-ειδικα αντισωματα και μεθοδοι χρησης αυτων
CY1115671T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
AR062895A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
AR037456A1 (es) Anticuerpos contra proteinas quimiotacticas monocitarias
BR0317376A (pt) Anticorpo humanizado (h14.18) do anticorpo 14.18 do camundongo que se liga a gd2 e sua fusão com il-2
CL2009002199A1 (es) Anticuerpo que se une especificamente a epitope de cripto; composicion farmaceutica que comprende dicho anticuerpo; uso del anticuerpo para disminuir el crecimiento de un tumor in vitro; metodo para modular el crecimiento de celulas de tumor in vitro en una muestra; anticuerpo humanizado (div. sol. n° 831-2002).
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
BR112014011144A2 (pt) tratamento de malignidades hematológicas com um anticorpo anti-cxcr4
CL2012003283A1 (es) Anticuerpo humano aislado o un fragmento de union al antigeno del mismo porque se une o bloquea la actividad biológica de gdf-8 humano maduro de tipo natural; composicion farmacéutica que comprende dicho anticuerpo o el fragmento de unión al antígeno; uso del anticuerpo para tratar una enfermedad o trastorno tratable mediante la inhibición de la actividad de gdf-8.
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
SV2006002131A (es) Uso de un anticuerpo para el tratamiento de lupus
CL2008003361A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composicones medias que los comprenden.
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
AR070821A1 (es) Anticuerpo anti- tyrp1 (antitiroxina humana)
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
AR115257A1 (es) Anticuerpos de fijación a bcma y sus usos
EA200970884A1 (ru) Способы лечения рака путем введения комбинаций человеческого интерлейкина ил-18

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150602